Atelocollagen Activates GlyT1 Glycine Transporter, Bypass Route to Collagen
The collagen supplement market grew complicated not because there are too many options, but because the assumption that collagen is just collagen has not gone away. A 2025 study in the International Journal of Molecular Sciences puts that assumption under pressure. For the first time, it maps how atelocollagen activates GlyT1, a glycine transporter protein, in aged skin fibroblasts, raising intracellular glycine levels and stimulating the cell’s own collagen synthesis machinery. The story is not about ingested collagen traveling to the skin. It is about changing how the cell absorbs glycine in the first place.
What Atelocollagen Actually Is
Native collagen molecules carry short tail sequences at both ends called telopeptides. These tails can trigger immune recognition and are a liability for medical or cosmetic applications. Atelocollagen is produced by precisely removing those telopeptide ends through enzyme treatment. What remains is the triple-helix core, the structure in which three polypeptide chains wind around each other, intact.
This is where the comparison with hydrolyzed collagen and low-molecular-weight collagen diverges. Both hydrolyzed and low-molecular-weight collagens are produced by breaking the triple helix entirely, using heat, acid, or enzymes, leaving short peptides in the 500 to 1,000 Da range. Absorption is easier, but the structural information of the triple helix is gone. Atelocollagen sits between the two: telopeptide-free for low antigenicity, triple-helix-intact for structural signaling.
GlyT1, the Protein That Carries Glycine Into the Cell
Glycine makes up 33 percent of collagen’s amino acid sequence. The repeating Gly-X-Y motif that defines collagen structure requires a glycine at every third position, which is what allows three chains to coil together. Without adequate glycine inside the cell, collagen synthesis stalls.
Aged dermal fibroblasts, the cells responsible for collagen production in the skin’s dermis, show reduced intracellular glycine. Simply consuming more glycine does not guarantee it reaches the cell interior; glycine needs the GlyT1 transporter protein to cross the cell membrane. GlyT1 has been studied primarily in the nervous system, but it is also expressed in skin fibroblasts. This study is the first to demonstrate its functional role in the context of skin aging.
When aged human dermal fibroblasts were treated with atelocollagen, both GlyT1 mRNA expression and protein levels increased significantly. Intracellular glycine concentration rose alongside. The same pattern was reproduced in aged mouse skin tissue.
Why Atelocollagen Outperforms Glycine Alone
Treating cells with glycine directly does increase collagen synthesis. But atelocollagen treatment produced greater results than glycine alone. The mechanism is a shuttle effect.
Atelocollagen, through its intact triple-helix structure, interacts with cell surface receptors and signaling pathways in a way that upregulates GlyT1 expression itself. When more transporters are present, the cell can pull more glycine from the extracellular environment. Providing glycine and expanding the channel that brings glycine into the cell are two different interventions. Atelocollagen acts on the channel.
The confirming experiment used a GlyT1 inhibitor, NFPS. When the inhibitor was added alongside atelocollagen, every effect, including collagen synthesis, glutathione elevation, and MMP suppression, was blocked. The pathway does not run without GlyT1.
SMAD2/3 Phosphorylation and Simultaneous Type I and III Collagen Synthesis
Once intracellular glycine accumulates, synthesis signals follow. Atelocollagen treatment induced phosphorylation, meaning activation, of SMAD2 and SMAD3. These are central mediators of the TGF-beta signaling pathway and act as transcription factors that switch on collagen synthesis genes.
As a result, both type I collagen, the primary structural protein in the skin’s dermis, and type III collagen, involved in elasticity and tissue repair, increased simultaneously. The fact that both types rise together matters. Aging skin shows an imbalance between type I and type III collagen ratios that contributes to loss of firmness. Stimulating both pathways at once goes beyond simply adding more collagen.
Histological analysis of mouse skin confirmed the change at the tissue level, showing increased collagen fiber density and measurable improvement in skin elasticity.
MMP Suppression Through the NF-kB Pathway
Collagen synthesis rising while degradation stays the same limits the net benefit. Atelocollagen addressed both sides of the equation.
Treatment raised intracellular glutathione levels and reduced markers of oxidative stress. As oxidative stress decreased, NF-kB transcription factor activity was suppressed. NF-kB is a primary driver of MMP expression. MMP1, MMP3, and MMP9, all matrix metalloproteinases that degrade collagen, showed reduced expression. The chain runs from glycine to glutathione to oxidative stress reduction to NF-kB suppression to lower MMP activity, operating in parallel with the collagen synthesis increase.
Hydrolyzed Collagen, Low-Molecular-Weight Collagen, and Atelocollagen Compared
The practical difference between the three forms comes down to how their structure interacts with cells.
Hydrolyzed and low-molecular-weight collagens are fully fragmented peptides. After absorption through the gut, they reach tissue via the bloodstream and serve either as raw material for collagen synthesis or as signals to cell surface receptors. Absorption efficiency is high, but structural signaling, the information conveyed by an intact triple helix, is absent.
Atelocollagen reaches cells with the triple-helix structure preserved. As this study demonstrated, that structure is what drives GlyT1 upregulation and SMAD pathway activation. The intervention is not just supplying glycine as substrate but widening the cell’s capacity to absorb it.
Neither approach is categorically superior. They represent different mechanisms of action, and the relevant question is which pathway fits a given formulation, target, and individual physiology.
Applications in Aesthetic Treatments, Fillers, Skin Boosters, and Topical Formulations
Atelocollagen has a long history in aesthetic medicine beyond oral supplementation. Its low antigenicity from telopeptide removal makes it compatible with fillers, skin boosters administered by intradermal injection, and topical delivery systems.
The current findings came from an oral administration context, but the mechanism by which atelocollagen activates GlyT1 at the cellular level carries implications for these applied forms. If atelocollagen reaches dermal fibroblasts directly through injection or topical delivery, GlyT1 upregulation in those cells could provide an additional explanation for the collagen regeneration response observed after such treatments. Whether the mechanism operates identically in injectable or topical formats awaits further investigation.
Q. Does oral atelocollagen show immediate effects on skin?
Atelocollagen is broken down into amino acids during digestion. This study clarified how cells absorb glycine through the GlyT1 transporter pathway and use it to synthesize their own collagen. Rather than expecting immediate visible changes, a continuous intake of four to eight weeks or more is a more realistic timeframe for metabolic shifts to accumulate.
Q. Would GlyT1 inhibitors block the benefits?
In the study, adding a GlyT1 inhibitor (NFPS) completely blocked all effects of atelocollagen, including collagen synthesis, glutathione elevation, and MMP suppression. This confirms GlyT1 is the essential switch. Any compound or drug that inhibits GlyT1 in daily use could potentially reduce efficacy, though real-world interaction data remain limited.
Q. Should I choose atelocollagen over hydrolyzed collagen?
The difference is structural. Atelocollagen retains its triple-helix structure after removing the telopeptide ends, while hydrolyzed collagen is fully fragmented into short peptides. This study showed the intact triple-helix structure of atelocollagen is what activates the GlyT1 shuttle more effectively. Whether one form suits you better depends on your formulation, concentration, and digestive capacity.